Following a series of changes to the technologies due to be appraised, NICE considers there is limited value to the NHS in conducting an MTA of the remaining second line renal cell carcinoma therapies (axitinib, sorafenib and sunitinib). The Institute has decided to remove this appraisal from its current work programme.
 
Status Suspended
Process MTA

Project Team

Project lead Stephanie Yates

Email enquiries

Consultees

Companies sponsors Bayer (sorafenib)
  Novartis Pharmaceuticals (everolimus)
  Pfizer (axitinib and sunitinib)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Kidney Cancer Support Network
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups None
Comparator companies None
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
31 March 2016 Suspended, Following a series of changes to the technologies due to be appraised, NICE considers there is limited value to the NHS in conducting an MTA of the remaining second line renal cell carcinoma therapies (axitinib, sorafenib and sunitinib). The Institute has decided to remove this appraisal from its current work programme.
09 February 2016 Invitation to participate
19 January 2016 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance